Literature DB >> 15460184

Enterococcus faecalis resistant to linezolid: case series and review of the literature.

Brian S Burleson1, David J Ritchie, Scott T Micek, W Michael Dunne.   

Abstract

Reports of linezolid resistance among Enterococcus faecalis have been relatively rare. We describe three patients with linezolid-resistant strains of E. faecalis, discovered after the patients had received long courses (> 30 days) of linezolid therapy. All strains contained the G2576U mutation in 23S rRNA. A literature review revealed one other case in the United States and three cases in Europe; all involved patients who had received long courses of therapy. It appears that recent or extended linezolid therapy may be a risk factor for development of resistant E. faecalis. In patients who have recently been treated with linezolid and have an identified new systemic enterococcal isolate, linezolid sensitivity should be verified as soon as possible to guide therapy. This strategy also should be considered for patients with a breakthrough enterococcal isolate during linezolid therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15460184     DOI: 10.1592/phco.24.13.1225.38086

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

1.  Central venous catheter colonization by linezolid-resistant, vancomycin-susceptible Enterococcus faecalis.

Authors:  Alexandre R Marra; Yvette Major; Michael B Edmond
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

2.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

3.  Detection of mutations conferring resistance to linezolid in Enterococcus spp. by fluorescence in situ hybridization.

Authors:  Guido Werner; Melanie Bartel; Nele Wellinghausen; Andreas Essig; Ingo Klare; Wolfgang Witte; Sven Poppert
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

4.  Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

Authors:  Jeffrey B Locke; John Finn; Mark Hilgers; Gracia Morales; Shahad Rahawi; Kedar G C; Juan José Picazo; Weonbin Im; Karen Joy Shaw; Jeffrey L Stein
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

5.  Multiple roles for Enterococcus faecalis glycosyltransferases in biofilm-associated antibiotic resistance, cell envelope integrity, and conjugative transfer.

Authors:  Jennifer L Dale; Julian Cagnazzo; Chi Q Phan; Aaron M T Barnes; Gary M Dunny
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 6.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

7.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

8.  Mevalonate 5-diphosphate mediates ATP binding to the mevalonate diphosphate decarboxylase from the bacterial pathogen Enterococcus faecalis.

Authors:  Chun-Liang Chen; James C Mermoud; Lake N Paul; Calvin Nicklaus Steussy; Cynthia V Stauffacher
Journal:  J Biol Chem       Date:  2017-10-12       Impact factor: 5.157

9.  Visualizing the enzyme mechanism of mevalonate diphosphate decarboxylase.

Authors:  Chun-Liang Chen; Lake N Paul; James C Mermoud; Calvin Nicklaus Steussy; Cynthia V Stauffacher
Journal:  Nat Commun       Date:  2020-08-07       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.